Drug survival dei farmaci biologici per la psoriasi moderato-severa: analisi dei fattori associati alla sospensione del farmaco in 425 pazienti ​

Etanercept, Adalimumab, Infliximab, Ustekinumab, Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab Tildrakizumab are among the biologic drugs used for the treatment of Psoriasis. Objectives: (i) To assess the relative drug survival of Etanercept, Adalimumab, Infliximab, Ustekinumab, Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab Tildrakizumab in patients with psoriasis. (ii) To investigate factors associated with drug withdrawal. (iii) To investigate drug survival of Etanercept, Adalimumab, Infliximab, Ustekinumab, Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab Tildrakizumab. (iv) To compare drug survival of Etanercept, Adalimumab, Infliximab, Ustekinumab, Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab Tildrakizumab to previously used regimens